Article Figures & Data
Figures
- Figure 1.
Patient distribution by minimum number of weeks of methotrexate (MTX) therapy received during open-label adalimumab (ADA) treatment.
- Figure 2.
Percentages of patients demonstrating 28-joint Disease Activity Score (DAS28) remission (A), 70% improvement in the American College of Rheumatology rating scale response criteria (ACR70) (B), and ACR90 (C) during the open-label period. Includes all patients with nonmissing data at each timepoint.
- Figure 3.
Mean Health Assessment Questionnaire (HAQ) scores during randomized and open-label adalimumab (ADA) treatment. Includes all patients with nonmissing data at each timepoint. MTX: methotrexate; RCT: randomized controlled trial.
- Figure 4.
Radiographic scores from baseline to Year 5. Broken lines represent the full randomized study population. Solid lines represent the 5-year completers cohort. A, B, and C present results for modified total Sharp score (mTSS), joint erosion (JE), and joint space narrowing (JSN), respectively. ADA: adalimumab; MTX: methotrexate; RCT: randomized controlled trial.
- Figure 5.
Percentages of patients in the 5-year completers cohort with nonmissing data who met triple criteria for comprehensive disease remission at Year 5. ADA: adalimumab; DAS28: 28-joint Disease Activity Score; HAQ: Health Assessment Questionnaire; mTSS: modified total Sharp score; MTX: methotrexate.
Tables
- Table 1.
Baseline disease characteristics in the randomized and 5-year completers cohorts. Statistics are group means except where noted.
Characteristic Randomized Cohort* 5-Year Completers Cohort by Original Randomization Arm ADA+MTX, n = 268 ADA, n = 274 MTX, n = 257 ADA+MTX, n = 124 ADA, n = 115 MTX, n = 115 RA duration, yrs 0.7 0.7 0.8 0.8 0.7 0.8 SJC (66) 21.1 21.8 22.1 21.1 21.0 22.9 TJC (68) 30.7 31.8 32.3 30.7 32.8 31.6 DAS28 6.3 6.4 6.3 6.3 6.3 6.2 HAQ 1.5 1.6 1.5 1.4 1.6 1.5 CRP, mg/dl 3.9 4.1 4.0 3.9 3.7 3.7 mTSS 18.1 18.8 21.9 15.5 16.8 19.5 JE 11.0 11.3 13.6 9.4 9.7 10.7 JSN 7.1 7.5 8.2 6.1 7.1 8.8 Estimated annual mTSS progression, median† 28.5 29.6 25.6 24.0 23.9 21.9 -
↵* Data from Breedveld, et al11 except for “estimated annual mTSS progression.”
-
↵† Median of the estimated individual patient annual mTSS progression. ADA: adalimumab; DAS28: 28-joint Disease Activity Score; HAQ: Health Assessment Questionnaire; JE: joint erosions; JSN: joint space narrowing; mTSS: modified total Sharp score; MTX: methotrexate; SJC: swollen joint count; TJC: tender joint count.
-
